Additionally, in breast cancer and melanoma, Itgβ8 ablation in Treg cells impairs TGFβ signaling in intra-tumoral T lymphocytes, which strengthen the effector function of CD8+ TILs, leading to efficient control of tumor growth [86]. The gene discussed is CD8A; the disease is breast carcinoma.